Nanomedicines in the treatment of hepatitis C virus infection in Asian patients: optimizing use of peginterferon alfa
Chen-Hua Liu,1–3 Jia-Horng Kao1–3 1Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan; 2Hepatitis Research Center, National Taiwan University Hospital, Taipei, Taiwan; 3Graduate Institute of Clinical Medicine, National Taiwan University College...
Guardado en:
Autores principales: | Liu CH, Kao JH |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://doaj.org/article/4cafce75a1344b9094832d9572293735 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Resultados del tratamiento con peginterferón alfa-2a y ribavirina en pacientes con hepatitis crónica C
por: Pizarro,Carolina, et al.
Publicado: (2011) -
Ombitasvir, paritaprevir, and ritonavir with peginterferon-α2a plus ribavirin in treatment-experienced patients with chronic hepatitis C virus genotype 1 infection
por: Bernstein D, et al.
Publicado: (2019) -
Recombinant follitropin alfa/lutropin alfa in fertility treatment
por: Ahmed Gibreel, et al.
Publicado: (2009) -
Population pharmacokinetics of peginterferon α2a in patients with chronic hepatitis B
por: Jingfeng Bi, et al.
Publicado: (2017) -
Public optimism towards nanomedicine
por: Magrini A, et al.
Publicado: (2011)